Line 105: | Line 105: | ||
<h3><span>Abstract:</span><br></h3> | <h3><span>Abstract:</span><br></h3> | ||
<h3>Ginseng products offer unique opportunity to meet the atherosclerosis challenge. Herbs containing ginsenosides include: Ginseng, Western Ginseng, Notoginseng, Jiaogulan etc. Current herb preparation and administration practice results in poor absorption profile limit its efficacy and cost-effectiveness. Since the ginseno-sterols are responsible for their main pharmacological effects, how to achieve effective concentration of sterol in the human body become critical. <br> Our long-term goal is to improve the health-promoting effects of ginsenosides. We believe that sterols (triterpenes)in the ginsenosides are responsible for their main benefits. Therefore in the past projects we engineered synthetic squalene cyclase for in situ production of ginseng-sterols in human cells and produced synthetic β-glucosidase in E.coli for removal of sugar from ginsenosides. In the current strategy, in the wake of “No release” policy of the iGEM community, we are able to by-pass synthetic biology methods to achieve our goal by applying in vitro chemical reactions. </h3> | <h3>Ginseng products offer unique opportunity to meet the atherosclerosis challenge. Herbs containing ginsenosides include: Ginseng, Western Ginseng, Notoginseng, Jiaogulan etc. Current herb preparation and administration practice results in poor absorption profile limit its efficacy and cost-effectiveness. Since the ginseno-sterols are responsible for their main pharmacological effects, how to achieve effective concentration of sterol in the human body become critical. <br> Our long-term goal is to improve the health-promoting effects of ginsenosides. We believe that sterols (triterpenes)in the ginsenosides are responsible for their main benefits. Therefore in the past projects we engineered synthetic squalene cyclase for in situ production of ginseng-sterols in human cells and produced synthetic β-glucosidase in E.coli for removal of sugar from ginsenosides. In the current strategy, in the wake of “No release” policy of the iGEM community, we are able to by-pass synthetic biology methods to achieve our goal by applying in vitro chemical reactions. </h3> | ||
− | <div class=" | + | <div class="pad30"></div> |
<h3><span>In the past, two approaches have been tried to achieve this: </span></h3> | <h3><span>In the past, two approaches have been tried to achieve this: </span></h3> | ||
<h3>(1) Synthesize ginseno-sterols in situ Pro: no need to plant ginseng and harvest, continuous supply of ginseno-sterols; Con: interference with physiology, lack of control in production. <br> | <h3>(1) Synthesize ginseno-sterols in situ Pro: no need to plant ginseng and harvest, continuous supply of ginseno-sterols; Con: interference with physiology, lack of control in production. <br> | ||
(2) Produce beta-glucosides in the gut micro-organism. Pro: convenient to hydrolyze ginsenosides in the gut; Con: interference with gut physiology and probiotics.<br></h3> | (2) Produce beta-glucosides in the gut micro-organism. Pro: convenient to hydrolyze ginsenosides in the gut; Con: interference with gut physiology and probiotics.<br></h3> | ||
− | <div class=" | + | <div class="pad30"></div> |
<div><h3><span>In the current third approach</span>, we use chemical reaction to hydrolyze the conjugated sugars, to satisfy “No-release” policy if iGEM safety requirement.</h3> | <div><h3><span>In the current third approach</span>, we use chemical reaction to hydrolyze the conjugated sugars, to satisfy “No-release” policy if iGEM safety requirement.</h3> | ||
</blockquote></div> | </blockquote></div> | ||
Line 157: | Line 157: | ||
<div class="span10 pad15"> | <div class="span10 pad15"> | ||
<div class="vendor" > | <div class="vendor" > | ||
− | <iframe src=" | + | <iframe src=""></iframe> |
</div> | </div> | ||
</div> | </div> |
Revision as of 01:00, 14 October 2018